Therapeutic Potential of Antioxidants and Hybrid TEMPOL Derivatives in Ocular Neurodegenerative Diseases: A Glimpse into the Future

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2023 Nov 25

PMID 38001960

Authors

Charles E Amankwa

Bindu Kodati

Nina Donkor

Suchismita Acharya

Affiliations

Soon will be listed here.

Abstract

Reactive oxygen species play a significant role in the pathogenesis of various ocular neurodegenerative diseases especially glaucoma, age-related macular degeneration (AMD), and ocular ischemic stroke. Increased oxidative stress and the accumulation of ROS have been implicated in the progression of these diseases. As a result, there has been growing interest in exploring potential therapeutic and prophylactic strategies involving exogenous antioxidants. In recent years, there have been significant advancements in the development of synthetic therapeutic antioxidants for targeting reactive oxygen species (ROS) in neurodegenerative diseases. One area of focus has been the development of hybrid TEMPOL derivatives. In the context of ocular diseases, the application of next-generation hybrid TEMPOL antioxidants may offer new avenues for neuroprotection. By targeting ROS and reducing oxidative stress in the retina and optic nerve, these compounds have the potential to preserve retinal ganglion cells and trabecular meshwork and protect against optic nerve damage, mitigating irreversible blindness associated with these diseases. This review seeks to highlight the potential impact of hybrid TEMPOL antioxidants and their derivatives on ocular neurodegenerative disorders.

Citing Articles

Tert-butyl hydroperoxide induces trabecular meshwork cells injury through ferroptotic cell death.

Yan X, Liu Q, Wu S, Fan X, Teng Y, Wang N J Cell Commun Signal. 2024; 18(3):e12050.

PMID: 39524143 PMC: 11544637. DOI: 10.1002/ccs3.12050.

The Role and Mechanism of Nicotinamide Riboside in Oxidative Damage and a Fibrosis Model of Trabecular Meshwork Cells.

Zeng Y, Lin Y, Yang J, Wang X, Zhu Y, Zhou B Transl Vis Sci Technol. 2024; 13(3):24.

PMID: 38546981 PMC: 10981432. DOI: 10.1167/tvst.13.3.24.

References

Ung L, Pattamatta U, Carnt N, Wilkinson-Berka J, Liew G, White A . Oxidative stress and reactive oxygen species: a review of their role in ocular disease. Clin Sci (Lond). 2017; 131(24):2865-2883. DOI: 10.1042/CS20171246. View

Kamel K, Farrell M, OBrien C . Mitochondrial dysfunction in ocular disease: Focus on glaucoma. Mitochondrion. 2017; 35:44-53. DOI: 10.1016/j.mito.2017.05.004. View

Keller K, Acott T . The Juxtacanalicular Region of Ocular Trabecular Meshwork: A Tissue with a Unique Extracellular Matrix and Specialized Function. J Ocul Biol. 2013; 1(1):3. PMC: 3867143. View

Chan E, Liu G, Dusting G . Redox mechanisms in pathological angiogenesis in the retina: roles for NADPH oxidase. Curr Pharm Des. 2015; 21(41):5988-98. DOI: 10.2174/1381612821666151029111127. View

Baynes J, Thorpe S . Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes. 1999; 48(1):1-9. DOI: 10.2337/diabetes.48.1.1. View

Shahidullah M, Mandal A, Wei G, Delamere N . Nitric oxide regulation of Na, K-ATPase activity in ocular ciliary epithelium involves Src family kinase. J Cell Physiol. 2013; 229(3):343-52. PMC: 5985964. DOI: 10.1002/jcp.24454. View

Amatore D, Celestino I, Brundu S, Galluzzi L, Coluccio P, Checconi P . Glutathione increase by the n-butanoyl glutathione derivative (GSH-C4) inhibits viral replication and induces a predominant Th1 immune profile in old mice infected with influenza virus. FASEB Bioadv. 2020; 1(5):296-305. PMC: 6996388. DOI: 10.1096/fba.2018-00066. View

Ito F, Sono Y, Ito T . Measurement and Clinical Significance of Lipid Peroxidation as a Biomarker of Oxidative Stress: Oxidative Stress in Diabetes, Atherosclerosis, and Chronic Inflammation. Antioxidants (Basel). 2019; 8(3). PMC: 6466575. DOI: 10.3390/antiox8030072. View

Bortolanca Chiarotto G, Drummond L, Cavarretto G, Bombeiro A, de Oliveira A . Neuroprotective effect of tempol (4 hydroxy-tempo) on neuronal death induced by sciatic nerve transection in neonatal rats. Brain Res Bull. 2014; 106:1-8. DOI: 10.1016/j.brainresbull.2014.04.010. View

10.

Rao V, Epstein D . Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma. BioDrugs. 2007; 21(3):167-77. DOI: 10.2165/00063030-200721030-00004. View

11.

Neha K, Haider M, Pathak A, Shahar Yar M . Medicinal prospects of antioxidants: A review. Eur J Med Chem. 2019; 178:687-704. DOI: 10.1016/j.ejmech.2019.06.010. View

12.

Chaphalkar R, Stankowska D, He S, Kodati B, Phillips N, Prah J . Endothelin-1 Mediated Decrease in Mitochondrial Gene Expression and Bioenergetics Contribute to Neurodegeneration of Retinal Ganglion Cells. Sci Rep. 2020; 10(1):3571. PMC: 7046667. DOI: 10.1038/s41598-020-60558-6. View

13.

Wilcox C . Effects of tempol and redox-cycling nitroxides in models of oxidative stress. Pharmacol Ther. 2010; 126(2):119-45. PMC: 2854323. DOI: 10.1016/j.pharmthera.2010.01.003. View

14.

Pham J, Johnson G, Rangan R, Amankwa C, Acharya S, Stankowska D . Neuroprotection of Rodent and Human Retinal Ganglion Cells In Vitro/Ex Vivo by the Hybrid Small Molecule SA-2. Cells. 2022; 11(23). PMC: 9735605. DOI: 10.3390/cells11233741. View

15.

Wheeler L, WoldeMussie E, Lai R . Role of alpha-2 agonists in neuroprotection. Surv Ophthalmol. 2003; 48 Suppl 1:S47-51. DOI: 10.1016/s0039-6257(03)00004-3. View

16.

Nassiri-Asl M, Naserpour Farivar T, Abbasi E, Sadeghnia H, Sheikhi M, Lotfizadeh M . Effects of rutin on oxidative stress in mice with kainic acid-induced seizure. J Integr Med. 2013; 11(5):337-42. DOI: 10.3736/jintegrmed2013042. View

17.

Datta S, Cano M, Ebrahimi K, Wang L, Handa J . The impact of oxidative stress and inflammation on RPE degeneration in non-neovascular AMD. Prog Retin Eye Res. 2017; 60:201-218. PMC: 5600827. DOI: 10.1016/j.preteyeres.2017.03.002. View

18.

Armstrong D . Lipid peroxidation and retinopathy in streptozotocin-induced diabetes. Free Radic Biol Med. 1991; 11(4):433-6. DOI: 10.1016/0891-5849(91)90161-u. View

19.

Inoue K, Fujimoto T, Higa R, Moriyama R, Kohmoto H, Nagumo H . Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapy. Clin Ophthalmol. 2012; 6:771-5. PMC: 3367435. DOI: 10.2147/OPTH.S31085. View

20.

Amankwa C, Gondi S, Dibas A, Weston C, Funk A, Nguyen T . Novel Thiol Containing Hybrid Antioxidant-Nitric Oxide Donor Small Molecules for Treatment of Glaucoma. Antioxidants (Basel). 2021; 10(4). PMC: 8068288. DOI: 10.3390/antiox10040575. View